These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34873228)

  • 41. Ursodeoxycholic acid in advanced polycystic liver disease: A phase 2 multicenter randomized controlled trial.
    D'Agnolo HM; Kievit W; Takkenberg RB; Riaño I; Bujanda L; Neijenhuis MK; Brunenberg EJ; Beuers U; Banales JM; Drenth JP
    J Hepatol; 2016 Sep; 65(3):601-7. PubMed ID: 27212247
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of baseline parameters in the HALT polycystic kidney disease trials.
    Torres VE; Chapman AB; Perrone RD; Bae KT; Abebe KZ; Bost JE; Miskulin DC; Steinman TI; Braun WE; Winklhofer FT; Hogan MC; Oskoui FR; Kelleher C; Masoumi A; Glockner J; Halin NJ; Martin DR; Remer E; Patel N; Pedrosa I; Wetzel LH; Thompson PA; Miller JP; Meyers CM; Schrier RW;
    Kidney Int; 2012 Mar; 81(6):577-85. PubMed ID: 22205355
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The zebrafish as a model to study polycystic liver disease.
    Tietz Bogert PS; Huang BQ; Gradilone SA; Masyuk TV; Moulder GL; Ekker SC; Larusso NF
    Zebrafish; 2013 Jun; 10(2):211-7. PubMed ID: 23668934
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of mTOR inhibitor therapy in patients with early-stage autosomal dominant polycystic kidney disease: a meta-analysis of randomized controlled trials.
    He Q; Lin C; Ji S; Chen J
    Am J Med Sci; 2012 Dec; 344(6):491-7. PubMed ID: 22902868
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Use of  Prophylactic Somatostatin Therapy Following Pancreaticoduodenectomy: A Meta-analysis of Randomised Controlled Trials.
    Adiamah A; Arif Z; Berti F; Singh S; Laskar N; Gomez D
    World J Surg; 2019 Jul; 43(7):1788-1801. PubMed ID: 30798417
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
    Temmerman F; Chen F; Libbrecht L; Vander Elst I; Windmolders P; Feng Y; Ni Y; De Smedt H; Nevens F; van Pelt J
    World J Gastroenterol; 2017 Aug; 23(30):5499-5507. PubMed ID: 28852309
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD): Somatostatin analogues and mTOR inhibitors].
    Perico N; Cortinovis M; Remuzzi G
    G Ital Nefrol; 2016; 33(5):. PubMed ID: 27796020
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL; Meijer E; Visser FW; Engels GE; Kappert P; Losekoot M; Peters DJM; Gansevoort RT;
    Am J Nephrol; 2019; 50(5):375-385. PubMed ID: 31600749
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
    Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
    Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of octreotide on polycystic liver volume.
    van Keimpema L; Drenth JP
    Liver Int; 2010 Apr; 30(4):633-4. PubMed ID: 19744163
    [No Abstract]   [Full Text] [Related]  

  • 51. Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.
    Messchendorp AL; Casteleijn NF; Meijer E; Gansevoort RT
    Nephrol Dial Transplant; 2020 Aug; 35(8):1306-1316. PubMed ID: 31077332
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Vitamin D supplementation for chronic liver diseases in adults.
    Bjelakovic G; Nikolova D; Bjelakovic M; Gluud C
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011564. PubMed ID: 29099543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Development and validation of a polycystic liver disease complaint-specific assessment (POLCA).
    Temmerman F; Dobbels F; Ho TA; Pirson Y; Vanslembrouck R; Coudyzer W; Bammens B; van Pelt J; Pirenne J; Nevens F
    J Hepatol; 2014 Nov; 61(5):1143-50. PubMed ID: 24996047
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system.
    Nunes VS; Correa JM; Puga ME; Silva EM; Boguszewski CL
    Pituitary; 2015 Aug; 18(4):500-8. PubMed ID: 25261979
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease.
    Horie S; Muto S; Kawano H; Okada T; Shibasaki Y; Nakajima K; Ibuki T
    Clin Exp Nephrol; 2021 May; 25(5):467-478. PubMed ID: 33471240
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.
    Ji XQ; Ruan XJ; Chen H; Chen G; Li SY; Yu B
    Med Sci Monit; 2011 Aug; 17(8):RA169-176. PubMed ID: 21804474
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The relationship between liver cyst volume and QOL in Japanese ADPKD patients.
    Muto S; Ando M; Nishio S; Hanaoka K; Ubara Y; Narita I; Kamura K; Mochizuki T; Tsuchiya K; Tsuruya K; Horie S
    Clin Exp Nephrol; 2020 Apr; 24(4):314-322. PubMed ID: 31875934
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Questionnaire PLD-complaint-specific assessment identifies need for therapy in polycystic liver disease: A multi-centric prospective study.
    Billiet A; Temmerman F; Coudyzer W; Van den Ende N; Colle I; Francque S; De Maeght S; Janssens F; Orlent H; Sprengers D; Delwaide J; Decock S; De Vloo C; Moreno C; van Malenstein H; van der Merwe S; Verbeek J; Nevens F
    United European Gastroenterol J; 2023 Sep; 11(7):633-641. PubMed ID: 37278135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Meta-analysis of randomized controlled trials on the effectiveness of somatostatin analogues for pancreatic surgery: a Cochrane review.
    Koti RS; Gurusamy KS; Fusai G; Davidson BR
    HPB (Oxford); 2010 Apr; 12(3):155-65. PubMed ID: 20590882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease.
    Masyuk TV; Radtke BN; Stroope AJ; Banales JM; Masyuk AI; Gradilone SA; Gajdos GB; Chandok N; Bakeberg JL; Ward CJ; Ritman EL; Kiyokawa H; LaRusso NF
    Gastroenterology; 2012 Mar; 142(3):622-633.e4. PubMed ID: 22155366
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.